Telmisartan
Indications
Telmisartan is used for:
Hypertension, Diabetic nephropathy
Adult Dose
Oral
Hypertension
Adult: Initially, 40 mg once daily, may be adjusted to 20-80 mg once daily if needed.
Elderly: 20 mg/day PO initially;
Cardiovascular risk reduction
Adult: 80 mg once daily.
Hepatic impairment: Mild to moderate: Max: 40 mg once daily. Severe: Contraindicated.
Child Dose
<18 years old: Safety and efficacy not established
Renal Dose
Renal impairment: Severe impairment or on haemodialysis: Initially, 20 mg once daily.
Administration
May be taken with or without food.
Contra Indications
Severe hepatic impairment, biliary obstructive disorders. Pregnancy. Lactation.
Precautions
Hepatic insufficiency, biliary obstruction, renal impairment, renaly artery stenosis. Correct volume depletion before initiating treatment. Monitor serum potassium levels regularly, especially in elderly and renally-impaired patients.
Pregnancy-Lactation
Pregnancy category: 1st trimester, C; 2nd and 3rd trimesters, D
Interactions
May increase plasma levels of digoxin. May increase serum lithium levels and toxicity. May reduce plasma levels of warfarin. Increased risk of hyperkalaemia w/ K-sparing diuretics, K supplements or K-containing salt substitutes. May antagonise hypotensive effect and increase risk of renal impairment w/ NSAIDs.
Potentially Fatal: May increase nephrotoxic, hyperkalaemic and hypotensive effect w/ aliskiren in patients w/ diabetes and renal impairment (GFR <60 mL/min).
Adverse Effects
Side effects of Telmisartan :
1-10%
Upper respiratory tract infection (URTI) (7%),Back pain (3%),Diarrhea (3%),Myalgia (3%),Sinusitis (3%),Chest pain (1%),Hypertension (1%),Headache (1%),Dizziness (1%),Pharyngitis (1%)
<1%
Abnormal ECG,Anemia,Angina,Angioedema,Bradycardia,Eczema,Epistaxis,Gout,Hypercholesterolemia,Hyperkalemia,Hypoglycemia,Otitis media
Potentially Fatal: Rarely angioedema, rash, pruritus and urticaria.
Mechanism of Action
Telmisartan is a nonpeptide AT1 angiotensin II receptor antagonist. It exerts antihypertensive activity by preventing angiotensin II from binding to AT1 receptors thus inhibiting the vasoconstricting and aldosterone-secreting effects of angiotensin II.